GDC 0084

Drug Profile

GDC 0084

Alternative Names: GDC-0084; RG 7666

Latest Information Update: 04 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioma

Most Recent Events

  • 30 Oct 2016 GDC 0084 licensed to Novogen worldwide
  • 30 Oct 2016 Novogen plans a phase II trial for Glioblastoma (in patients wit) in USA in fourth quarter of 2017
  • 28 Jan 2015 Discontinued - Phase-I for Glioma in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top